Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2015 /
Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

18th - 22nd Apr 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.15
Views: 1756
Rating:

Dr David Bajor - University of Pennsylvania, Philadelphia, USA

Dr Bajor talks to ecancertv at AACR 2015 about combining the immunostimulatory anti-CD40 monoclonal antibody CP- 870,893 with the immune checkpoint inhibitor tremelimumab in advanced melanoma. This approach was found to be safe, with clinical evidence of response.

Read the news story for more.

 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation